Sales of Novo Nordisk’s blockbuster weight-loss drug Wegovy have seen a remarkable increase, doubling in the fourth quarter as interest in obesity treatments grows. However, the Danish pharmaceutical company has issued a warning regarding the overall sales growth trajectory of its drugs, including Ozempic, slated for a decline in the coming year. This slowing growth comes after a period of unprecedented demand and significant market presence in the weight-loss sector, which was buoyed by increased health awareness and new medical endorsements over the past few years. As the market stabilizes, stakeholders are encouraged to stay informed on Novo Nordisk’s strategic adjustments in response to evolving consumer needs. To learn more about these developments, visit the original article at [Quartz](https://qz.com/novo-nordisk-ozempic-wegovy-sales-1851755300).